Go Pro
NASDAQ:CSBR

Champions Oncology Q4 2026 Earnings Report

Champions Oncology logo
$6.12 +0.24 (+4.08%)
Closing price 07/8/2026 03:58 PM Eastern
Extended Trading
$6.01 -0.11 (-1.80%)
As of 07/8/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Champions Oncology EPS Results

Actual EPS
N/A
Consensus EPS
-$0.05
Beat/Miss
N/A
One Year Ago EPS
N/A

Champions Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
$12.89 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Champions Oncology Announcement Details

Quarter
Q4 2026
Time
After Market Closes
Conference Call Date
Wednesday, July 22, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Champions Oncology Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Champions Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Champions Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Champions Oncology and other key companies, straight to your email.

About Champions Oncology

Champions Oncology (NASDAQ:CSBR) engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

View Champions Oncology Profile